Research Article

Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation with Fe(III) and Image Scanning Densitometry

Volume: 11 Number: 3 August 30, 2024
EN

Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation with Fe(III) and Image Scanning Densitometry

Abstract

Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain or inflammation due to osteoarthritis or rheumatoid arthritis. Assay of piroxicam in pharmaceutical formulations can be performed by using a number of analytical techniques. This work estimates the drug in commercial samples using a novel method, Computational Image Scanning Densitometry (CISD). Micro-volumes of the aqueous solution of piroxicam were reacted with iron(III) sulfate solution under optimum conditions on a white Teflon well plate to form a pink-colored mononuclear complex. By using a smartphone, the picture of the colored complex in the well plate was taken and transferred to an attached computer. The overall optical density resulting from red, green, and blue (RGB) components from a specific area of the colored image was measured and digitalized with the help of custom-made software. A standard curve was prepared by plotting optical density against piroxicam concentration. The method was simple, fast, adequately precise, and accurate for the assay of the drug in commercial samples. The validity of the new method was checked by comparing the results with those obtained by a standard spectrophotometric method of Piroxicam estimation.

Keywords

References

  1. 1. Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti‐inflammatory drugs and beyond. IUBMB Life [Internet]. 2014 Dec 23;66(12):803–11. Available from: .
  2. 2. Shojaee SA, Rajaei H, Hezave AZ, Lashkarbolooki M, Esmaeilzadeh F. Experimental measurement and correlation for solubility of piroxicam (a non-steroidal anti-inflammatory drugs (NSAIDs)) in supercritical carbon dioxide. J Supercrit Fluids [Internet]. 2013 Aug 1;80:38–43. Available from: .
  3. 3. Wiseman EH, Cchang YH, Lombardino JG. Piroxicam, a novel anti-inflammatory agent. Chem Informationsd [Internet]. 1976 Oct 12;7(41):1300–3. Available from: .
  4. 4. Brogden RN, Heel RC, Speight TM, Avery GS. Piroxicam A reappraisal of its pharmacology and therapeutic efficacy. Drugs [Internet]. 1984 Oct 15;28(4):292–323. Available from: .
  5. 5. Laake K, Kjeldaas L, Borchgrevink CF. Side‐effects of piroxicam (Feldene®). Acta Med Scand [Internet]. 1984 Jan 12;215(1):81–3. Available from: .
  6. 6. Azmi SNH, Iqbal B, Jaboob MAM, Al Shahari WAS, Rahman N. Spectrophotometric determination of piroxicam via chelation with Fe(III) in commercial dosage forms. J Chinese Chem Soc [Internet]. 2009 Dec 25;56(6):1083–91. Available from: .
  7. 7. Dragomiroiu ABGT, Cimpoieşu A, Ginghină O, Baloescu C, Bârcă M, Popa DE, et al. The development and validation of a rapid HPLC method for the determination of piroxicam. Farmacia [Internet]. 2015;63(1):123–31. Available from: .
  8. 8. Dikram SB, Mahmood RM. High performance liquid chromatographic method for the determination of Piroxicam, Naproxen, Diclofenac Sodium, and Mefenamic Acid in Bulk Drug and Pharmaceutical Preparations. Pure Appl Sci [Internet]. 2018;26(5):387–99. Available from: .

Details

Primary Language

English

Subjects

Analytical Spectrometry

Journal Section

Research Article

Early Pub Date

July 26, 2024

Publication Date

August 30, 2024

Submission Date

December 14, 2023

Acceptance Date

July 3, 2024

Published in Issue

Year 2024 Volume: 11 Number: 3

APA
Anwar, J., Dar, A., Mumtaz, R., Anzano, J., & Mohyuddin, A. (2024). Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation with Fe(III) and Image Scanning Densitometry. Journal of the Turkish Chemical Society Section A: Chemistry, 11(3), 1245-1254. https://doi.org/10.18596/jotcsa.1391053
AMA
1.Anwar J, Dar A, Mumtaz R, Anzano J, Mohyuddin A. Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation with Fe(III) and Image Scanning Densitometry. JOTCSA. 2024;11(3):1245-1254. doi:10.18596/jotcsa.1391053
Chicago
Anwar, Jamıl, Amara Dar, Ramna Mumtaz, Jesús Anzano, and Ayesha Mohyuddin. 2024. “Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation With Fe(III) and Image Scanning Densitometry”. Journal of the Turkish Chemical Society Section A: Chemistry 11 (3): 1245-54. https://doi.org/10.18596/jotcsa.1391053.
EndNote
Anwar J, Dar A, Mumtaz R, Anzano J, Mohyuddin A (August 1, 2024) Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation with Fe(III) and Image Scanning Densitometry. Journal of the Turkish Chemical Society Section A: Chemistry 11 3 1245–1254.
IEEE
[1]J. Anwar, A. Dar, R. Mumtaz, J. Anzano, and A. Mohyuddin, “Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation with Fe(III) and Image Scanning Densitometry”, JOTCSA, vol. 11, no. 3, pp. 1245–1254, Aug. 2024, doi: 10.18596/jotcsa.1391053.
ISNAD
Anwar, Jamıl - Dar, Amara - Mumtaz, Ramna - Anzano, Jesús - Mohyuddin, Ayesha. “Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation With Fe(III) and Image Scanning Densitometry”. Journal of the Turkish Chemical Society Section A: Chemistry 11/3 (August 1, 2024): 1245-1254. https://doi.org/10.18596/jotcsa.1391053.
JAMA
1.Anwar J, Dar A, Mumtaz R, Anzano J, Mohyuddin A. Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation with Fe(III) and Image Scanning Densitometry. JOTCSA. 2024;11:1245–1254.
MLA
Anwar, Jamıl, et al. “Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation With Fe(III) and Image Scanning Densitometry”. Journal of the Turkish Chemical Society Section A: Chemistry, vol. 11, no. 3, Aug. 2024, pp. 1245-54, doi:10.18596/jotcsa.1391053.
Vancouver
1.Jamıl Anwar, Amara Dar, Ramna Mumtaz, Jesús Anzano, Ayesha Mohyuddin. Microdetermination of Piroxicam in Pharmaceutical Formulations by Complexation with Fe(III) and Image Scanning Densitometry. JOTCSA. 2024 Aug. 1;11(3):1245-54. doi:10.18596/jotcsa.1391053

Cited By